Trial Outcomes & Findings for Multifocal Lens Design Evaluation (NCT NCT01997216)

NCT ID: NCT01997216

Last Updated: 2014-02-04

Results Overview

The participant read a Snellen chart at 40 centimeters with both eyes together while wearing study lenses. The Snellen acuity was converted into logMAR units (logarithm of the minimum angle of resolution). A 20/20 Snellen acuity equates to a logMAR acuity of 0.0 and is considered normal near eyesight. A negative logMAR value denotes better visual acuity.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

42 participants

Primary outcome timeframe

Up to Hour 9

Results posted on

2014-02-04

Participant Flow

Participants were recruited from 1 study center located in the United States.

Of the 42 participants enrolled, 1 participant was exited as a screen failure and 1 participant was discontinued due to product unavailability prior to study product exposure. This reporting group includes all enrolled participants exposed to study product (40).

Participant milestones

Participant milestones
Measure
Delefilcon A MF, Then AOAMF
Delefilcon A multifocal contact lenses, followed by lotrafilcon B multifocal contact lenses, as randomized. Each product was worn bilaterally (in both eyes) for 9 hours. The wear periods were separated by 2 ± 1 days.
AOAMF, Then Delefilcon A MF
Lotrafilcon B multifocal contact lenses, followed by delefilcon A multifocal contact lenses, as randomized. Each product was worn bilaterally (in both eyes) for 9 hours. The wear periods were separated by 2 ± 1 days.
First 9 Hours
STARTED
18
21
First 9 Hours
COMPLETED
18
21
First 9 Hours
NOT COMPLETED
0
0
Second 9 Hours
STARTED
19
21
Second 9 Hours
COMPLETED
19
21
Second 9 Hours
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Multifocal Lens Design Evaluation

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Overall
n=40 Participants
Delefilcon A multifocal contact lenses and lotrafilcon B multifocal contact lenses, worn as randomized for 9 hours each.
Age, Continuous
52.1 years
STANDARD_DEVIATION 6.0 • n=5 Participants
Sex: Female, Male
Female
25 Participants
n=5 Participants
Sex: Female, Male
Male
15 Participants
n=5 Participants

PRIMARY outcome

Timeframe: Up to Hour 9

Population: All enrolled participants exposed to study product. 1 participant was not exposed to Delefilcon A MF due to product unavailability.

The participant read a Snellen chart at 40 centimeters with both eyes together while wearing study lenses. The Snellen acuity was converted into logMAR units (logarithm of the minimum angle of resolution). A 20/20 Snellen acuity equates to a logMAR acuity of 0.0 and is considered normal near eyesight. A negative logMAR value denotes better visual acuity.

Outcome measures

Outcome measures
Measure
Delefilcon A MF
n=39 Participants
Delefilcon A multifocal contact lenses worn bilaterally (in both eyes) for 9 hours
AOAMF
n=40 Participants
Lotrafilcon B multifocal contact lenses worn bilaterally (in both eyes) for 9 hours
Mean Binocular HC/HI Visual Acuity at Near (40 cm)
Dispense (Hour 0)
0.08 logMAR
Standard Deviation 0.10
0.06 logMAR
Standard Deviation 0.09
Mean Binocular HC/HI Visual Acuity at Near (40 cm)
Hour 9
0.05 logMAR
Standard Deviation 0.08
0.05 logMAR
Standard Deviation 0.10

SECONDARY outcome

Timeframe: Up to Hour 9

Population: All enrolled participants exposed to study product. 1 participant was not exposed to Delefilcon A MF due to product unavailability.

The participant read a Snellen chart at a 20-foot equivalent distance with both eyes together while wearing study lenses. The Snellen acuity was converted into logMAR units (logarithm of the minimum angle of resolution). A 20/20 Snellen acuity equates to a logMAR acuity of 0.0 and is considered normal distance eyesight. A negative logMAR value denotes better visual acuity.

Outcome measures

Outcome measures
Measure
Delefilcon A MF
n=39 Participants
Delefilcon A multifocal contact lenses worn bilaterally (in both eyes) for 9 hours
AOAMF
n=40 Participants
Lotrafilcon B multifocal contact lenses worn bilaterally (in both eyes) for 9 hours
Mean Binocular HC/HI Visual Acuity at Distance
Dispense (Hour 0)
-0.06 logMAR
Standard Deviation 0.04
-0.06 logMAR
Standard Deviation 0.04
Mean Binocular HC/HI Visual Acuity at Distance
Hour 9
-0.05 logMAR
Standard Deviation 0.08
-0.05 logMAR
Standard Deviation 0.05

SECONDARY outcome

Timeframe: Up to Hour 9

Population: All enrolled participants exposed to study product. OR data is included for the 1 participant not exposed to Delefilcon A MF due to product unavailability.

OR is the amount of additional correction needed to improve visual acuity (VA). The OR at dispense was conducted with non-study product to determine lens power for the 9-hour wear. Dispensing of the study product (Pair 1 and Pair 2) was dependent upon lens power as determined by OR and resultant product availability. The OR at 9 hours was conducted with study product. All OR data is reported regardless whether study product was dispensed. Each eye contributed to the mean.

Outcome measures

Outcome measures
Measure
Delefilcon A MF
n=40 Participants
Delefilcon A multifocal contact lenses worn bilaterally (in both eyes) for 9 hours
AOAMF
n=40 Participants
Lotrafilcon B multifocal contact lenses worn bilaterally (in both eyes) for 9 hours
Mean Monocular Over-refraction (OR) at Distance
Dispense (Hour 0)
0.08 diopter
Standard Deviation 0.14
0.06 diopter
Standard Deviation 0.13
Mean Monocular Over-refraction (OR) at Distance
Hour 9
0.06 diopter
Standard Deviation 0.13
0.03 diopter
Standard Deviation 0.12

Adverse Events

Delefilcon A MF

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

AOAMF

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Joachim Nick, Dipl.-Ing. (FH), Clinical Lead

Alcon Research, Ltd.

Phone: 1-888-451-3937

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place